TENAX THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
TENAX THERAPEUTICS, INC. (TENX) reported Share-based Payment Arrangement, Expense of $2.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-07-31
- TENAX THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $2.80M, a 37.78% decline year-over-year.
- TENAX THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.70M, a 32.50% decline year-over-year.
- TENAX THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.80M, a 397.41% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $5.50M, a 61011.11% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $18.80M, a 1780.00% increase from fiscal 2024.
- TENAX THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $1.00M, a 762.07% increase from fiscal 2023.
- TENAX THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $116.00K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-07-31 | $5.60M 10-Q · filed 2026-07-31 | $10.30M derived: sum of 3 quarters · filed 2026-07-31 | $15.80M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-12 | $7.50M derived: sum of 2 quarters · filed 2026-05-12 | $13.00M derived: sum of 3 quarters · filed 2026-05-12 | $17.50M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $10.30M derived: sum of 2 quarters · filed 2026-03-10 | $14.80M derived: sum of 3 quarters · filed 2026-07-31 | $18.80M 10-K · filed 2026-03-10 | |
| 2025-09-30 | $5.50M 10-Q · filed 2025-11-12 | $10.00M derived: sum of 2 quarters · filed 2026-07-31 | $14.00M 10-Q · filed 2025-11-12 | $14.96M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-06-30 | $4.50M 10-Q · filed 2026-07-31 | $8.50M 10-Q · filed 2026-07-31 | $9.46M derived: sum of 3 quarters · filed 2026-07-31 | $9.47M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-03-31 | $4.00M 10-Q · filed 2026-05-12 | $4.96M derived: sum of 2 quarters · filed 2026-05-12 | $4.97M derived: sum of 3 quarters · filed 2026-05-12 | $4.98M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $965.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $974.00K derived: sum of 2 quarters · filed 2026-03-10 | $984.00K derived: sum of 3 quarters · filed 2026-03-10 | $1.00M 10-K · filed 2026-03-10 | $998.00K 10-K · filed 2025-03-25 |
| 2024-09-30 | $9.00K 10-Q · filed 2025-11-12 | $19.00K derived: sum of 2 quarters · filed 2025-11-12 | $35.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $10.00K 10-Q · filed 2025-08-13 | $28.00K 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $16.00K 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | $116.00K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |